Beisol Pharma Tienen: what changed
What changed
Beisol Pharma Tienen
NACE 77.400, Rental and leasing activities
filed annual accounts (NBB)
Net result for the year
€2,648
2025 · €2,670-€22
Equity
-€49,165
2025 · -€51,814+€2,649
Cash
€48
2025 · €243-€195
Balance sheet total
€121,648
2025 · €126,414-€4,766
Largest movements
Assets
- Receivables within one year -€4,571
down €4,571 (-22.3%), from €20,523 to €15,952
of which Trade receivables: -€5,600
Equity and liabilities
- Trade debts -€10,500
no longer reported in 2026 (was €10,500)
- Other debts +€3,085
up €3,085 (+1.8%), from €167,728 to €170,813
- Profit (loss) carried forward +€2,649
up €2,649 (+4.3%), from -€62,029 to -€59,380
Income statement
No income-statement line moved by more than 1% of the activity.
Change in the result, 2025 to 2026
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Result 2025
€2,670
Gross operating margin
+€9
Other operating charges
-€13
Financial charges
-€18
Result 2026
€2,648
raises the resultlowers the result
Derived cash bridge
The bridge is derived from the 2025 and 2026 balance sheets and the 2026 result. There is no filed cash-flow statement. You see where the money came from and where it went.
From operations
-€196
Investment
€0
Financing
+€1
Cash 2025
€243
From operations (derived)
-€196
Net result for the year
+€2,648
Receivables within one year
+€4,571
Trade debts
-€10,500
Other debts
+€3,085
Financing
+€1
Contributions, distributions and other
+€1
Cash 2026
€48
brings cash intakes cash out
Every line side by side
| Line | Code | 2025 | 2026 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €126,414 | €121,648 | -€4,766 | -3.8% |
| Current assets | 29/58 | €126,414 | €121,648 | -€4,766 | -3.8% |
| Stocks and contracts in progress | 3 | €105,648 | €105,648 | = | 0.0% |
| Stocks | 30/36 | €105,648 | €105,648 | = | 0.0% |
| Amounts receivable within one year | 40/41 | €20,523 | €15,952 | -€4,571 | -22.3% |
| Trade receivables | 40 | €19,600 | €14,000 | -€5,600 | -28.6% |
| Other amounts receivable | 41 | €923 | €1,952 | +€1,029 | +111% |
| Cash at bank and in hand | 54/58 | €243 | €48 | -€195 | -80.2% |
| Total equity and liabilities | 10/49 | €126,414 | €121,648 | -€4,766 | -3.8% |
| Equity | 10/15 | -€51,814 | -€49,165 | +€2,649 | +5.1% |
| Contributions | 10/11 | €6,200 | €6,200 | = | 0.0% |
| Capital | 10 | €6,200 | €6,200 | = | 0.0% |
| Issued capital | 100 | €18,600 | €18,600 | = | 0.0% |
| Uncalled capital | 101 | €12,400 | €12,400 | = | 0.0% |
| Reserves | 13 | €4,015 | €4,015 | = | 0.0% |
| Non-distributable reserves | 130/1 | €201 | €201 | = | 0.0% |
| Legal reserve | 130 | €201 | €201 | = | 0.0% |
| Distributable reserves | 133 | €3,814 | €3,814 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€62,029 | -€59,380 | +€2,649 | +4.3% |
| Amounts payable | 17/49 | €178,228 | €170,813 | -€7,415 | -4.2% |
| Amounts payable within one year | 42/48 | €178,228 | €170,813 | -€7,415 | -4.2% |
| Trade debts | 44 | €10,500 | - | -€10,500 | |
| Suppliers | 440/4 | €10,500 | - | -€10,500 | |
| Other amounts payable | 47/48 | €167,728 | €170,813 | +€3,085 | +1.8% |
| Turnover | 70 | €11,200 | €11,200 | = | 0.0% |
| Goods, raw materials, services and sundry goods | 60/61 | €8,113 | €8,104 | -€9 | -0.1% |
| Other operating charges | 640/8 | €387 | €400 | +€13 | +3.4% |
| Gross operating margin | 9900 | €3,087 | €3,096 | +€9 | +0.3% |
| Operating profit (loss) | 9901 | €2,700 | €2,696 | -€4 | -0.1% |
| Financial charges | 65/66B | €30 | €48 | +€18 | +60.0% |
| Recurring financial charges | 65 | €30 | €48 | +€18 | +60.0% |
| Profit (loss) for the period before taxes | 9903 | €2,670 | €2,648 | -€22 | -0.8% |
| Profit (loss) for the period | 9904 | €2,670 | €2,648 | -€22 | -0.8% |
| Profit (loss) for the period to be appropriated | 9905 | €2,670 | €2,648 | -€22 | -0.8% |
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Compare this company with its sector.Sector benchmark
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 March 2025 and 31 March 2026. Green is a favourable move for that line, red an unfavourable one. Prepared on 4 November 2026 via checked.be.